DNM1L and juvenile Huntington disease: Strikingly, while inhibiting the interaction between Drp1 and Fis1 slowed the progression of neurodegenerative disorders7–10, treatment with the Drp1/Mff-specific inhibitor accelerated disease progression in a mouse model of Huntington’s Disease.